Factors that affect adherence to antiretroviral therapy among adolescent patients at selected Palapye clinics by Kambale, Herve Nzereka
 
 
Factors that affect adherence to 
antiretroviral therapy among adolescent 
patients at selected Palapye clinics 
 
by  
 
Hervé Nzereka Kambale 
March 2013  
Assignment presented in fulfilment of the requirements for the degree of 
Master of Philosophy (HIV/AIDS Management) in the faculty of 
Economic and Management Sciences at Stellenbosch University 
Supervisor: Dr Greg Munro 
 
 
 
 
 
i 
 
Declaration 
 
By submitting this assignment electronically, I declare that the entirety of the work contained 
therein in my own, original work, that I am the sole author thereof (save to the extent 
explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch 
University will not infringe any third party rights and that I have not previously in its entirety 
or in part submitted it for obtaining any qualification 
 
Date: March 2013 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2013 Stellenbosch University 
 
All rights reserved 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
ii 
 
 
 
Acknowledgements 
 
I am grateful to Dr Greg Munro for his technical input and review of this research study, and 
for providing me with valuable comments and guidance. I wish also to acknowledge my co-
researchers and all participants from the respective clinics for their support and assistance 
during the data collection process. I would also like to acknowledge the Setswana junior 
school teacher who gave her time at short notice to translate the research tools into Setswana. 
 
Likewise, I would like to thank my wife, Rosalie Masika, my children, Caroline Masika, Joel 
Kasay, Adhemar Pondi, Yan Muyisa, my mother Charlotte Masika, and my brother, Dr Arsene 
Kambale, and Adhemar Kambale for their support and assistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
iii 
 
 
Abstract 
 
This study, which was conducted from 1 to 31 October 2012, was aimed at describing the 
main factors that influence adolescent adherence to antiretroviral treatment in three selected 
health facilities of Palapye Health District. During the one-month data collection period, 30 
adolescents were interviewed using semi-structured interview tools. 
 
Different factors influencing adolescent adherence to antiretroviral treatment were highlighted 
and adherence to such treatment was measured using the method of calculating the percentage 
of returned pills. The mean adherence level for the entire sample was 76.96%, with common 
factors contributing to poor adherence among adolescents being found to be the poor 
processing of disclosure, stigma, the accessibility of health facilities, due distance and waiting 
time, the nature of social support, and feelings toward taking antiretroviral. Thus, by 
addressing adolescent adherence to antiretroviral treatment, adolescent-adherence counselling 
before and during treatment is to be shaped, insisting on the preparation of young patient 
caregivers for the process of disclosure; the reinforcement of positive messages during 
consultations; insistence on the importance of disclosing HIV status to others; the 
implementation of the antiretroviral dispensing outreach at health posts; and exerting effort to 
reduce the waiting time at health facilities prioritising young patients and adolescents.  
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Opsomming 
 
Hierdie studie, wat vanaf 1 tot 31 Oktober 2012 onderneem is, het ten doel gehad om die 
hooffaktore te beskryf wat adolessente se getrouheid met antiretrovirale behandeling in drie 
gekose gesondheidsfasiliteite in die Palapye-gesondheidsdistrik beïnvloed. 
Semigestruktureerde onderhoude is gedurende die maand lange datainsamelingstydperk met 
30 adolessente gevoer. 
 
Die studie dui op verskillende faktore wat adolessente se getrouheid met antiretrovirale 
behandeling beïnvloed, welke getrouheid gemeet is aan die hand van die persentasie 
teruggestuurde pille. Die gemiddelde getrouheidsvlak vir die algehele steekproef was 76,96%. 
Algemene faktore wat oënskynlik tot swak behandelingsgetrouheid onder adolessente bydra, 
is die swak verwerking van MIV-statusonthulling, stigma, die toeganklikheid van 
gesondheidsfasiliteite, reisafstand en wagtyd, die aard van maatskaplike steun, en gevoelens 
oor die gebruik van antiretrovirale middels. Hierdie ondersoek na adolessente se getrouheid 
met antiretrovirale behandeling behoort adolessentberading oor behandelingsgetrouheid voor 
én gedurende behandeling te rig. Die klem moet in die besonder val op die voorbereiding van 
die versorgers van jong pasiënte om die onthullingsproses beter te hanteer; die versterking van 
positiewe boodskappe gedurende konsultasies; die belang van MIV-statusonthulling aan 
ander; die inwerkingstelling van uitreikaksies om voorskrifte vir antiretrovirale middels by 
sogenaamde ‘gesondheidstasies’ te resepteer, en daadwerklike pogings om die wagtyd by 
gesondheidsfasiliteite te verkort, met voorrang aan jong pasiënte en adolessente.  
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1.  INTRODUCTION 
 
1.1 Accessing antiretroviral therapy (ART) 
 
According to the UNAIDS Report on the Global Aids Epidemic published in 2010, by the end 
of 2009 more than five million people were receiving antiretroviral therapy (ART) for the first 
time, which meant an increase of 30% in the number of people receiving treatment in a single 
year. Overall, the number of people receiving therapy has grown 13-fold since 2004, with 
more than five million people in low- and middle-income countries, consisting of 36% of the 
15 million people in such countries who are in need of such treatment, receiving ART. 
Expanding access to treatment has contributed to a 19% decline in deaths among people living 
with HIV between 2004 and 2009 (UNAIDS, 2010, p. 95). 
 
Botswana is still one of the countries that is most severely affected by the HIV epidemic, with 
a national prevalence rate of 17.6% in 2008 (BAIS III, 2008). The national prevalence among 
pregnant women between 15 and 49 years old who were attending government antenatal 
clinics was 31.8% in 2008. 
 
Botswana was the first country in sub-Saharan Africa to launch a free national ART 
programme in the public health sector. Since then, the country has achieved among the 
world’s highest coverage rates for HIV treatment, delivering antiretroviral (ARV) drugs in 
2010 to more than 94.5% of those who needed the medication (UNAIDS, 2010, p. 98) 
 
1.2 Lack of adherence to the ART regimen 
 
Whereas highly active antiretroviral therapy (HAART) has significantly improved the lives of 
many HIV patients worldwide, the lack of adherence to the treatment remains a major 
challenge to HIV and acquired immune deficiency syndrome (AIDS) care, which is having 
serious public health consequences. The failure to adhere to HAART often leads to treatment 
failure and to the likelihood of accelerating the emergence of drug-resistant strains of HIV. As 
Botswana scales up access to ART in all its health facilities, there is a critical need to estimate 
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and to monitor the rates of adherence concerned. It is also important to understand the factors 
that influence adherence, in order to facilitate the design of appropriate interventions (Joyce et 
al., 2004, p. 9).  
 
1.3 Focus of the current study 
 
The current study was conducted in three clinics situated in Palapye District, in the Central 
region of Botswana. The clinics concerned, which are situated in the Maokatumo, Maunatlala 
and Lerala villages, provide ARV drugs on a weekly basis, apart from other primary health 
services. 
 
More than two thousand HIV-positive patients, including a number of adolescents aged 
between 13 and 20 years, are currently receiving HAART within the three selected study sites. 
The reports of poor adherence to HAART among the HIV-positive patients aged between 13 
and 20 years necessitated the current research. 
 
1.4 Accessing HAART 
 
HAART has been proven to be effective in suppressing HIV replication, in decreasing 
morbidity and mortality rates associated with HIV, and in improving the quality of life in 
adults, as well as in children, infected with HIV. However, many factors can affect the ability 
of HAART to suppress viral replication, including the low potency of one of the drugs in the 
combination, viral resistance, inadequate drug exposure, and inadequate adherence to therapy 
(Starace, Massa, Amico & Fisher, 2006, p. 154). Drugs do not work in patients who do not 
take them, and, in the management of HIV infection, it is now well established that optimum 
adherence to HAART is critical to the successful outcome of patients receiving therapy. At 
least 95% adherence to HAART is optimum, and studies have shown that <95% adherence is 
associated with a virologic failure rate of >50% (Shah, 2007, p. 55). 
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1.5 Growing concern regarding levels of adherence to the ART regimen 
 
Although ART has been available through the public sector in Botswana since 2002, there is 
continuing concern regarding the level of adherence, especially among adolescents. Studies 
conducted in Botswana have reported adherence levels of 83% (Nwokike, 2004) in the public 
sector and 54% (Weiser et al., 2003) in the private sector, being rates that are below the 
minimum level of 95% that is required for treatment success and for the delaying of the 
emergence of drug-resistant strains. 
 
To date, studies in Africa and in developed countries in other continents have mainly reported 
on adherence rates, with few of them being qualitative studies reporting on barriers to 
adherence in infants and adults. Therefore, qualitative studies are required to identify the 
barriers to, and facilitators of, adherence among adolescents on such continents and in such 
countries. Important factors that influence adherence to HAART, such as regimen-related 
complexities, patient-/family-related issues and factors that are related to the healthcare 
delivery system, make adherence to HAART challenging. Numerous interventions to improve 
adherence have been cited and investigated in studies conducted in both developed and 
developing countries, with one of the most important noted among them being counselling.  
 
Many HIV management policies are focusing on the counselling that is required to improve 
the outcome of the ART undertaken. In Botswana, pre-treatment and on-going counselling is 
offered to all patients both before and during the treatment, but the reasons are not known why 
HIV-positive adolescents tend to adhere poorly to HAART, compared to how other age groups 
do. 
 
1.6 Research regarding poor adherence to the HAART regimen 
 
The research question for the current study was: ‘What are the main factors that contribute to 
poor adherence to HAART among adolescent patients aged between 13 and 20 years old?’ 
The identified factors will be used in recommendations aimed at enhancing adolescent 
HAART adherence levels, in order to improve the ARV programme’s effectiveness. 
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Numerous research reports have been published regarding adherence to HAART among adults 
and children in many countries. However, limited information has been published about 
adherence to HAART among adolescent patients. The results of the current study could add to 
the existing body of knowledge regarding adolescent adherence to ART in sub-Saharan Africa 
in general, and particularly in Botswana. Policy-makers could consider the importance of the 
results of the present study for improving adolescent adherence to ART in Botswana. Health 
care providers working in facilities providing ART could utilise the results of the study to 
improve the quality of pre-treatment and on-going adherence counselling among adolescents.   
 
Improvement in adhering to HAART would contribute significantly to a reduction in the 
transmission of the HIV infection horizontally among youth and vertically from mother to 
child. 
 
 A significant reduction in prevalence among youth of 15-24 years old has been observed in 
Botswana, and, because the group concerned is normally used as a proxy for new infection, it 
is believed that, by reinforcing the strength of adherence counselling, the level of adherence 
among adolescents should be enhanced. Such intervention would considerably influence the 
reduction in the number of new HIV infections. In 2009, HIV prevalence in the age group 15-
19 years and 20-24 years was 13.2% and 24.1%, respectively, in comparison with the 24.7% 
and 38.7% prevalence in the same age groups, respectively, in 2001 (BAIS III, 2008, p. 13). 
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2. LITERATURE REVIEW 
 
2.1 Non-adherence to the ART regimen among adolescents 
 
In the majority of low- and middle-income countries, HIV has become a chronic disease since 
the implementation of universal access to HAART. Successful ART results in the suppression 
of HIV replication, and halts the clinical progression of the disease. A clear, positive 
relationship between ARV adherence and the achieving and maintaining of virological 
suppression has been established. Non-adherence to ART, evidenced as missed doses, is 
associated with incomplete viral suppression, and with the development of a drug-resistant 
virus, which, eventually, is bound to limit therapeutic options (Machtinger et al., 2006, p. 
514). 
 
Adherence is defined as “the extent to which a patient’s behaviour coincides with the 
prescribed healthcare regimen, as agreed upon through a shared decision-making process 
between the patient and the health care provider” (KITSO AIDS Training Program, 2010). 
Very high (greater than 95%) levels of adherence are required for ARV drugs to be effective 
and to prevent the emergence of resistant viral strains. Such high levels of adherence require 
missing out on no more than three doses a month for a twice-daily regime, and maintaining 
said level of adherence year after year (Zuurmond, 2008, p. 5) 
 
An adolescent is defined by the World Health Organisation (WHO) as a person who is 
between 10-19 years of age. About 1.2 billion adolescents exist worldwide, with one in every 
five people in the world being an adolescent (WHO. Regional Office for South-East Asia, 
2012). The Botswana Ministry of Health’s definition of an adolescent as a person who is aged 
between 13 and 20 years old is used in the current study (Botswana. Ministry of Health, 2008, 
p. 30).   
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2.2 The importance of obtaining optimal levels of adherence to the ART regimen  
 
A dramatic reduction in HIV-related morbidity and mortality rates has been recognised in 
countries where HAART has been made widely available (Anna et al., 2002). However, it is 
also recognised that extremely high levels of adherence to ART (at least 95%) are needed to 
ensure optimal benefits, and that maintaining such high levels may often be complex, in terms 
of the pill burden, the dietary restriction, and the dosing frequency involved. Where adherence 
to said regime is suboptimal, HIV rapidly selects for resistance, in part due to rapid and error- 
prone replication (Joyce et al., 2004, p. 17). 
 
It has been estimated that one-quarter (25%) of ART users in Africa do not achieve optimal 
adherence. Of even greater concern is the fact that a more recent systematic review of African 
ART treatment programmes calculated that up to 40% of all patients receiving ARVs are 
thought to have died or discontinued treatment within two years of starting on ARVs 
(Zuurmond, 2008, p. 6) 
 
The goal and benefit of HAART may be defined both clinically and biologically. Clinically, 
HAART prolongs life and improves the quality of life of those living with HIV, by reducing, 
as much as possible, the frequency of the HIV-related illness that is known as AIDS. By 
reducing the mortality rate due to AIDS, ARV drugs also have the controversial effect of 
increasing the number of people living with HIV, because they tend to live much longer than 
they would do without the treatment. Biologically, HAART is responsible for the immune 
reconstitution that is both quantitative (referring to the CD4 cell count in normal range) and 
qualitative (referring to the pathogen-specific immune response). HAART also causes the 
greatest possible reduction in viral load (preferably to less than 50 c/mL) for as long as 
possible, in order to halt disease progression and to prevent or to delay progression (Bartlett, 
Gallant & Conradie, 2008, p. 38).  
 
Adherence to treatment is critical to obtain the full benefits possible from HAART. The 
maximal and durable suppression of viral replication reduces the destruction of CD4 cells, 
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helps to prevent viral resistance, promotes immune reconstitution, and slows down the 
progression of disease. 
 
The relationship between adherence to the ARV regime and the development of resistance is 
not linear. Patients with low adherence levels do not exert sufficient selection pressure to 
confer a replication advantage for drug-resistant mutants. Patients with high adherence levels 
suppress replication, and mutations do not occur. Resistance is opted for by patients with 
moderate adherence. While all ARV drugs are susceptible to resistance, the degree of 
susceptibility varies. A single viral mutation results in complete resistance to the non-
nucleoside reverse transcriptase inhibitors (NNRTIs), namely efavirenz and nevirapine. 
Similarly, lamivudine is rendered ineffective by a single mutation. In contrast, other 
nucleoside reverse transcriptase inhibitors (NRTIs) and the protease inhibitors (PIs) are more 
robust, requiring multiple viral mutations before resistance develops. 
 
Because a resistant virus is only generated if there is adequate drug pressure to drive the 
development of the mutations involved, different ARV classes are vulnerable at different 
adherence rates. Resistance to a PI is noted most frequently when adherence is between 80% 
and 95%, as high levels of drug are needed to create enough selective pressure to confer 
survival benefit on a virus with multiple mutations. Lower levels of drug do not create enough 
pressure, so that a wild-type virus will remain the dominant virus. 
 
Conversely, resistance to NNRTIs is more likely at <80% than at 80-95% adherence. The 
single mutation that confers resistance to an NNRTI does not impact on the virus’s ability to 
replicate. Higher drug levels suppress the virus, and do not allow generation of the mutation 
concerned. Lower levels of NNRTIs secondary to <80% adherence commonly cause 
resistance (Wilson, Cotton, Bekker, Meyers, Venter & Maartens, 2008, p. 515). 
 
Despite the above-mentioned complexities, the message to an individual on ART remains the 
same. Long-term viral suppression will only be achieved with near-perfect adherence (>95%).  
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Figure 1 below indicates virological failure rates in percentages and adherence to ART. 
   
Figure 1. Virological failure rates (%) and adherence to ART  
(Paterson, Swindells, Mohr, Brester, Vergis, Squier, Wagener & Singh, 2000) 
 
Paterson et al. (2000) found that adherence greater than 95% is needed to achieve virologic 
success, especially for PI-containing regimens. 
 
As the levels of adherence decreased, the viral loads increased sharply, in a dose–response 
effect. The study showed that 22% of patients with adherence of greater than 95%, 61% of 
patients with adherence between 80-94.9%, and 80% of patients with adherence levels of less 
than 80% demonstrated virological failure. Such failure was regarded as indicating the 
presence of detectable viral loads (Paterson et al., 2000). 
 
In countries with broad access to effective ART, the clinical benefits have been dramatic. Far 
fewer are progressing into becoming people with AIDS, hospital AIDS wards have practically 
emptied, and the age-adjusted death rate from HIV/AIDS has declined by more than 70%. 
Adherence to ART has emerged as both the major determinant and the Achilles' heel of said 
success. 
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The lack of ARV adherence is the second strongest predictor of progression to AIDS and death, 
after the CD4 count. Incomplete adherence to ART, however, is common in all groups of 
treated individuals. The average rate of adherence to ART is approximately 70%, despite the 
fact that long-term viral suppression requires near-perfect adherence. The resulting virologic 
failure diminishes the potential for long-term clinical success. Drug-resistant strains of HIV 
selected through ongoing replication in the presence of ART can also be transmitted to 
uninfected or drug-naive patients, leaving them with fewer treatment options. Non-adherence 
may eventually undermine the dramatic improvements in HIV-related health parameters seen in 
resource-rich countries, and expected in developing countries, as ART becomes more widely 
available. Adherence is not the only determinant of ART failure or success. Other factors 
include genetic differences in drug metabolism, severe baseline immune suppression, and prior 
drug resistance (Machtinger & Bangsberg, 2006). 
 
Whereas strict adherence to ART promotes viral suppression, poor adherence results in further 
immunosuppression and in resistance to ARV medications (Chakraborty et al., 2008, p. 458). If 
there is poor adherence, then there is a higher risk that drug resistance will develop, which will 
result in the need for the second-line drug regimen. Said regimen can be more difficult to 
administer than the first-line treatment, with the cost implications of such treatment being 
considerable for the already low-income countries, as the second-line drug regimen costs 
almost ten times more than does the first-line drug regimen. As a result, the long-term 
implications for the sustainability of ART in resource-poor countries are considerable, as WHO 
states. Drug resistance may result in the failure of the extensive global and national efforts to 
provide hope to people living with HIV (Zuurmond, 2008, p. 5).  
 
2.3 The importance of obtaining maximum compliance from adolescents in adhering 
to the ART regimen 
 
Adolescents who are infected with HIV also face challenges in adherence. Several studies have 
identified the ‘burden’ that is placed on them to continue with the medications, which restricts 
their lifestyle options, leading to a situation that discourages them from wanting to keep their 
medications with them. 
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The denial and fear of HIV infection, which is especially common among the newly diagnosed 
young, might lead to a refusal to initiate, or to continue with, ARV therapy. Mistrust of medical 
treatment, misinformation about HIV, lack of knowledge about the medications, and the lack of 
availability and efficacy of ART can all act as barriers to adherence among adolescents, due to 
their concern and lack of conviction about their treatment, leading to them not properly 
monitoring their abiding by their ARV therapy regimen (Xochihua-Diaz, 2009) 
 
Adolescents commonly experience such challenges as the taking of complex medication 
regimens and the following of a continuous medical care routine. However, adolescents might 
have long histories of poor adherence. Regardless of the mode of acquisition of the HIV 
infection, infected adolescents might have very low self-esteem, leading to depression, chaotic 
lifestyles, and drug addictions, together with mental illness and poor adaptation to the social 
environment of their disease, due to a lack of family and social support. Depression, alcohol or 
drug abuse, school truancy, and the experiencing of advanced HIV disease are correlated with 
non-adherence (Murphy, Belzer, Durako, Sarr, Wilson & Muenz, 2005). 
 
In Europe, it has been reported that Italian children who received ART from foster parents were 
more adherent than were those receiving drugs from their biological parents or other relatives. 
(Giacomet, Albano, Starace, De Franciscis, Giaquinto, Gattinara, Bruzzese, Gabiano, Galli, 
Vigano, Caselli & Guarino, 2003, p. 1398). Thus, it has been suggested that efforts to improve 
children’s adherence  to complex regimens should address the developmental, psychosocial and 
family factors that are significantly associated with non-adherence (Mellins, Brackis-Cott,  
Dolezal & Abrams, 2004, p. 1035) 
 
Numerous studies conducted in Africa have reported that the medical providers involved tend 
to believe that poverty and stigma are common barriers to ART adherence in poorly resourced 
countries (Brackis-Cott, Mellius, Abrams, Reval & Dolezal, 2003, p. 252). Families are known 
to struggle with poverty, mental health and substance abuse problems, and disclosure issues, 
especially when the adolescents concerned reach the age of knowledge and discernment. In 
Senegal, the provision of free ARV has been reported to have a positive impact on ART 
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adherence levels (Laniece, Ciss, Desclaux, Diop, Mbodj, Ndiaye, Sylla, Delaporte & Ndoye, 
2003, p. S103). A similar study conducted in Blantyre, Malawi, noted that the provision of free 
ARVs improved the stipulated programme’s quality, and reduced the number of ART 
defaulters (Van Oosterhout, Kumwenda, Hartung, Mhango & Zijlstra, 2007, p. 1241). Rosen, 
Ketlhapile, Sanne and Desilva (2007, p. 524) state that the non-drug costs of obtaining 
treatment, including transport costs and the loss of income, might limit access even to free 
ARVs. 
 
In Botswana, HIV-infected adolescents have special psychosocial issues that often lead to the 
following adherence problems: the denial of, and fear related to, HIV diagnosis; 
misunderstanding related to diagnosis and health needs; lack of belief in the efficacy of ARVs; 
the distrust of family practitioners and the healthcare system; low self-esteem and an 
unstructured, chaotic lifestyle; and limited familial and social support (Botswana. Ministry of 
Health, 2012, p. 80). 
 
The data suggest that adolescents might be less likely than younger children to maintain 
effective responses to ART, which is generally related to problems with non-adherence to ART 
and psychosocial concerns, particularly depression. Hence, the most critical aspect of providing 
appropriate care to HIV-infected adolescents is the close monitoring of their psychosocial 
health, although the health professionals providing ARVs to young patients are often unaware 
of such complexities. Few training initiatives are designed to ensure that healthcare providers 
understand the psychosocial and logistic challenges involved with having to take ARVs on a 
daily basis. Such an understanding of common barriers is of potential benefit to the effective 
discussion of adherence strategies with patients and their caretakers (Phelps, Hathcock, 
Werdenberg & Schutze, 2010, p. 1). 
 
2.4 Recommendations regarding the involvement of others in assisting with the ART 
compliance of adolescents   
 
All ART clinics should identify staff with an interest in adolescent care that could be used to 
help ensure continuity of care to HIV-infected adolescents. The designated staff members could 
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form a ‘therapeutic alliance’ with adolescents, aimed at helping them to handle challenges to 
their well-being. Such ‘continuity-of-care’ providers should explore with the adolescents in 
their care issues of sexuality, safe sex, substance abuse, barriers to adherence, and community 
support. Although adolescents are often knowledgeable regarding their own health care, and 
are capable of attending medical appointments alone, as well as of taking medications 
independently, responsible adults should still remain involved in their care. To ensure 
continuous adherence to medications, an adult adherence partner should directly observe 
ingestion of all doses, even when the adolescent has a history of good adherence. 
  
Peer support is also an important aspect of adolescent care. Due to the stigma that is involved, 
it is often difficult for adolescents to disclose their HIV status to their peers without fear of 
rejection. Clinics that have several HIV-positive teenagers should form peer support networks, 
such as teen clubs, at which the HIV-positive teens can meet and support one another. Such 
teen clubs, which were pioneered in Botswana, have been internationally recognised as forming 
an important part of key interventions for HIV-infected adolescents. (Botswana. Ministry of 
Health, 2012, p. 80). 
 
2.5 Measurement of adherence to the ART regimen 
 
There are no gold standards by which to measure adherence to medication. Many studies 
employ a number of methods, either alone or in combination, to measure the amount of 
adherence shown. The most common include: electronic drug monitoring (EDM) devices; pill 
counts; biochemical markers; pharmacy refill records; and various self-reporting tools, such as 
questionnaires and visual analogues. According to Gill et al. (2005), the hierarchy of adherence 
measures ranks physician and self-assessment reports the least accurate, the pill count 
intermediate, and the EDM the most accurate adherence marker. However, no single measure is 
appropriate for all settings or outcomes. The use of more than one measure of adherence has 
been found to allow for the strength of one method to compensate for the weakness of the 
other, and for the more accurate capturing of the information required to determine adherence 
levels (Vitolins, Rand, Rapp, Ribisi & Sevick, 2000). 
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2.5.1. Objective assessment 
 
Objective adherence measures include pill counts, which entail patients bringing their 
remaining pills back in their respective containers during all refill visits, with the pharmacy 
technician counting all returned medication in order to estimate the number of doses that have 
been taken. Said method is the most frequently used to calculate the percentage of adherence 
practised. Unfortunately, the method can be time-consuming in a busy facility, and, in the long 
term, patients who know the system well will discard their tablets in order to meet the expected 
100% adherence rate, although doing so is not common. In order to counter the patients making 
such a move, some pharmacists advise doing surprise or unannounced pill counts at the 
patients’ home when said practice is suspected. 
 
Another objective adherence measure employs pharmacy refill data, which has been shown to 
be capable of predicting virological failure and survival rates in Zambia and South African 
cohorts (Wilson et al., 2006, p. 516). The measure involved is the simplest method of 
objectively recording adherence, and is best suited to monitoring adherence in large ARV 
programmes. The number of times that a patient receives medication over a fixed period, such 
as a calendar year, is expressed as a percentage of the number of times that they should have 
collected medication, for example a patient collecting medication 11 times out of an expected 
12 times in the previous year means that they have practised 92% compliance with the regimen. 
 
Electronic monitoring, which is an adherence measure that entails using electronic devices 
fixed on the medication container cover that record each time that a bottle is opened, is only 
used in a research environment, due to the expense involved, and the need for computer and 
specific software to download the registered information on the return of the bottle. The 
method, however, is accepted as being one of the most accurate measures that is currently 
available. 
 
Therapeutic drug monitoring entails the measuring of the plasma concentration of the ARV 
drug. Due to its invasive nature, it is impractical for use as the only assessment measure of 
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adherence. However, the method can be used in research on failing patients, in order to 
measure the concentration and the absorption of ARV drugs. 
 
2.5.2. Subjective assessment 
 
Subjective adherence methods are notoriously insensitive, although improvement in results can 
be obtained by adopting non-judgemental attitudes and by gaining the patient’s trust (Wilson et 
al., 2008, p. 516). Subjective assessments include using recall questionnaires, which requires 
the pharmacy technician to ask the patient to recall doses missed over the preceding three days, 
with the percentage of adherence being calculated on the basis of the answer provided by the 
patient concerned. The method is the most widely used tool for collecting adherence data, but it 
can also be seen as weak, because it is based on the credibility of the patient involved. 
 
A 30-day visual analogue scale (VAS) of doses taken might be regarded as a faster and more 
efficient means of obtaining similar information to that which can be obtained using the recall 
questionnaire. 
 
However, all measures of adherence remain approximations, although they can be used to 
target individuals who require more intensive adherence interventions. 
 
2.6 Risk factors for poor adherence to the ART regimen among adolescents 
 
Factors that might have either a positive or a negative impact on an adolescent’s pill-taking 
behaviour may be divided into three categories: patient-related; regimen-related; and disease- 
related. With the simple regimens that are available as first-line therapy, the major impact on 
adherence occurs at the level of the interaction of individuals on therapy with their families, 
communities and health carers. Caregivers have an important role to play in the adherence of 
children and adolescents to the ARV regimen, with the rate of adherence seeming to differ, 
depending on the relationship between the patient and their caregivers. The more favourable 
the relationships are, the more likely an adolescent is to remain adherent to the regimen over 
time. More attention than is bestowed on it at present needs to be given regarding the time of 
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disclosure of their HIV status to adolescents. The value of an HIV-positive adolescent being 
properly prepared for the disclosure, so that they might come to accept the fact that they have 
been infected should not be underestimated in terms of the future adherence quality.  
 
2.7 Interventions aimed at improving adherence 
 
2.7.1. Pre-treatment interventions 
 
Individuals who start treatment should be well-prepared to do so. A standard information 
module should be presented to all patients, in order to ensure that they have a basic 
understanding of HIV and ART, prior to them starting a course of ARVs. Such instruction 
should also be offered to the carers of children and of adults with mental illness. A ‘treatment 
buddy’, identified by the patient where possible, should also be educated about HIV and ART. 
 
The above-mentioned information can be given by the peer educator or the counsellor over 
multiple group or individual sessions, during the week or two weeks prior to the initiation of 
ART, with said session of education being followed up on by simple questions that are set to 
check that the patient has understood what they have been told regarding their illness and the 
treatment thereof. 
 
2.7.2. Interventions during treatment 
 
The majority of ‘treatment-ready’ people who start therapy are adherent to the regimen, and 
might be expected to have a suppressed viral load within 6 month after the beginning of the 
treatment. However, such is not always the case, as some patients do not manage to take their 
prescribed medicine correctly, and others tire over time, and begin to miss out on doses, due to 
pill fatigue. Patients who are poor adherers need to be identified as soon as possible, and to be 
targeted to receive more intensive adherence counselling that is tailored to covering issues that 
might lead to non-adherence. Discussions with patients on the ways to resolve such issues, the 
repetition of initial adherence counselling, the use of pillboxes, and home visits by an 
adherence counsellor to assess domestic circumstances are required. 
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3. RESEARCH METHODOLOGY 
 
3.1 Research methods of enquiry utilised 
 
In the current study both quantitative and qualitative research methods of enquiry were 
utilised, targeting HIV-positive patients aged between 13 and 20 years who were registered at 
the identified study sites. 
  
Adherence rates were measured using two methods. The first method entailed using patient 
self-reporting or two-day recall, with the patient concerned being asked to recall the frequency 
and timing of taking medication (i.e. ARVs), as well as their food intake, over the two days 
prior to the date of the data collection. The second method consisted of a one-month pharmacy 
pill count that was calculated by subtracting the number of pills returned by a patient from the 
number of pills that had been issued to them at the start of the month. The amount remaining 
indicated how much medication had been used by the patient during said period. The amount 
used was then divided by the expected amount, multiplied by 100, to determine the percentage 
adherence per participant over the month in question. 
 
Information on how factors contributing to poor adherence were collected using semi- 
structured interviews with adolescent patients on HAART.  
 
3.2 Sampling method and sample size 
 
Adolescents struggling with adherence were referred by the consulting clinician to the 
researcher for the study. At the time of the current study, approximately 2 518 HIV-positive 
patients were receiving ARV within the three selected facilities; a convenience sampling 
method was used to enrol 30 patients aged between 13-20 years who have been on ARV for a 
minimum period of one years. Every third patient attending a scheduled clinic visit was 
referred by the clinician to the researcher assisted by a local health care worker for the 
interview. These patients were asked to participate in a voluntary interview with the 
Stellenbosch University  http://scholar.sun.ac.za
 
 
17 
 
researcher. Consent was obtained from these participants for ethical purposes, after the aims of 
the study were explained to them and that non-participation would not affect future treatment. 
 
3.3 Inclusion criteria 
 
The adolescent patients on HAART for a minimum of one year, as administered by the 
Maokatumo, Maunatlala or Lerala clinic, who demonstrated that they were willing to take part 
in the study were included in the population of the study. Consent was obtained directly from 
adolescents aged 18 years and over, and, for those aged between 13 and 17 years old, consent 
was requested from both the adolescents and the caregivers concerned.  
 
3.4 Data collection tool 
 
Data were collected using anonymous interviewing, developed on the basis of the literature 
review. The questionnaire, which was administered by the interviewer, included 28 closed- 
and open-ended questions to assess the knowledge possessed about HIV and what factors 
contributed to poor adherence among the participants.  
 
3.5 Data analysis and validation 
 
The qualitative method of data collection used in the current research study was the 
phenomenological method, which involved describing the experiences of groups of 
individuals. As described by Christensen, phenomenological research involves “getting inside 
of people’s heads” to see how they experience things (Christensen, Burke Johnson & Turner, 
2011, p. 368). The collected data were analysed by searching for significant statements that 
had particular relevance to poor adherence to HAART. The statements concerned were 
recorded verbatim, or close as possible to the participants’ own wording (Christensen et al., p. 
369). Formulated ‘meaning’ statements were organised into clusters or themes. Finally, a 
summary description of the essence or phenomenological structure of the phenomenon under 
consideration was produced by integrating the statements, their meaning, and the clusters that 
they formed. The internal validity method used was data triangulation, which is described by 
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Christensen as the use of multiple data sources. An effort was made to interview different 
adolescents in a range of age groups who attended three different clinics situated in various 
villages. Limitation to a single data source from which to draw accurate conclusions was, 
accordingly, avoided (Christensen et al., p. 367) 
 
The quantitative data were analysed, using Excel spread sheets. The data concerned underwent 
familiarisation, the development of a thematic framework, coding, charting and interpretation. 
The following variables were analysed: age; gender; the education level; the age of disclosure; 
the mode of disclosure; the length of time spent being aware of own HIV status; the feelings 
experienced regarding the taking of ARVs; the disclosure of HIV status to others (in terms of 
the amount of stigma involved); the support system; the side-effects of medication; own 
knowledge of HIV and ARVs; and distance from the health facility concerned.  
 
3.6 Ethical considerations and issues of confidentiality  
Permission to collect data was requested from the Ethics and Research Committee of the 
Ministry of Health of Botswana, from Stellenbosch University, and from the Palapye District 
Health Management Team. Compliance with ethical standards was achieved because all 
patients who participated in the study did so both anonymously and freely. No report indicated 
any specific patient’s contribution, meaning that such contribution was not specified according 
to the facility involved. All data were kept stored electronically and safely secured, with 
access thereto only being granted on the provision of a set personal password. The data 
concerned were deleted at the end of the study. In addition, each participant was requested to 
sign a voluntary consent form, stating that they agreed to participate in the study. 
 
  
Stellenbosch University  http://scholar.sun.ac.za
 
 
19 
 
4. RESULTS 
 
4.1 Demographics of the respondents 
 
4.1.1. Age and gender 
 
The age and gender of participants are given in given in Table 1 below. 
 
Table 1 
Age by gender 
Gender 13 
years 
14 
years 
15 
years 
16 
years 
17 
years 
18 
years 
19 
years 
20 
years 
Total 
Male 2 2 3 2 0 2 1 1 13 
(43.3%) 
Female 4 3 2 3 2 0 0 3 17 
(56.6%) 
Total 6 
(20%) 
5 
(16.6%) 
5 
(16.6%) 
5 
(16.6%) 
2 
(6.6%) 
2 
(6.6%) 
1 
(3.3%) 
4 
(13.3%) 
30 
(100%) 
 
More female participants took part in the study than did male participants. In percentage 
terms, 43.3% of participants were male and 56.6% were female. Adolescents of all relevant 
years were represented in the study. The mean age of participants was 15.7 years. The mean 
age for male participants was 15.8 years, whereas that for female participants was 15.6. The 
mean percentage of adherence for male participants was 72.2%, compared to 80.4% for female 
participants. 
 
Figure 2 below describes the percentage of adherence according to the age of the participants 
involved in the study. 
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Figure 2. Percentage of adherence mean by age  
 
Level of adherence to ART among adolescents appeared to be higher in early teenage years 
and tended to decrease as the adolescents grew older. 
 
4.1.2. Education level 
 
Almost all of the participants were attending school at the time of data collection, except for 
two (representing 6.7% of the sample), who stated that they had never attended school. The 
majority of participants were attending secondary junior school. None of them were studying 
at tertiary level. Figure 3 below indicates the education level of the participants. 
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Figure 3. Education level 
 
4.2 Results pertaining to the adherence of the participants to the ART regimen 
 
4.2.1. Percentage of adherence to the regimen 
 
Figure 4 below indicates the percentage of adherence to the ART regimen. 
 
 
Figure 4. Percentage of adherence to ART 
 
26.6% 
53.3% 
13.3% 
0% 
6.7% 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
Education level
Primary Secondary Junior Secondary Senior Tertiary None
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35
Series1
Stellenbosch University  http://scholar.sun.ac.za
 
 
22 
 
The lowest adherence percentage was 44%, whereas the highest was 94%, with the adherence 
mean for the entire population being 76.9%, which was lower than the required adherence rate 
of 95% necessary to ensure the success of the ART. The percentage of adherence mean for 
male participants was lower (72.4 %) than it was for female participants (80.5 %). 
 
Figure 5 below describes the percentage of adherence according to the education level, 
revealing that the lowest rate of adherence to ART was observed among the adolescents 
attending senior secondary school. The level of education was, therefore, found not to 
influence the level of adherence among the adolescents studied. 
  
 
Figure 5. Percentage of adherence mean by education level 
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4.2.2. Length of time of awareness regarding own HIV status 
 
Figure 6 below indicates the length of time of knowledge regarding own HIV status. 
 
 
Figure 6. Length of time of knowledge regarding own HIV-positive status 
 
The length of time of awareness of own HIV status varied amongst participants from 15 
months to seven years. The above figure shows that most of the male participants had been 
aware of their own HIV status for more than five years, but the majority of female participants 
had only been aware of their own HIV status from one to two years. 
 
Figure 7 below describes the variation of the percentage of adherence according to the length 
of time of awareness of participants’ own HIV status. The lowest level of adherence to ART 
was clearly observed as being during the first year after the disclosure of the HIV status of the 
adolescents to them, with the level tending to increase after three and four years, and tending 
to decrease again after five years.    
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Figure 7. Percentage of adherence mean by length of time of awareness of own HIV-
positive status 
 
4.2.3. Age of disclosure of HIV-positive status to patients 
 
The age of disclosure to patients was estimated by using the above-mentioned length of time 
of awareness of their own HIV status, together with the age of the participants. The mean age 
of disclosure was 12.3 years. Figure 8 below indicates the age of disclosure. 
 
 
Figure 8. Age of HIV-positive status disclosure to patients 
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Figure 9 below describes the variation in the percentage of adherence, according to the age of 
disclosure. Adherence to ART seemed to have stabilised at an acceptable level when the 
disclosure process was undertaken when the patient was between the age of nine and eleven, 
but adherence was seen to be negatively affected when the disclosure process was performed 
at a later age. 
 
Figure 9. Percentage of adherence mean by age at which disclosure occurred 
 
4.2.4. Mode of disclosure 
Figure 10 below indicates the mode of disclosure. 
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PMTCT = prevention of mother-to-child transmission 
 
The majority of participants stated that they had become aware of their own HIV status when 
they presented themselves for testing when they did not feel well, or indirectly, when they 
were brought to the clinic on the ARV scheduled day, or when they were prescribed ARVs. 
Only four of them (13.3%) had been told by their relatives, and none of the participants were 
told about their HIV status at the clinic by a health care provider. 
 
Some of the participants’ statements related to the mode of disclosure are listed as follow:  
No one told me about my HIV status, but I realised it myself, because I was always brought 
to the clinic on Thursday, which is an ARV-scheduled day at Maunatlala Clinic.  
 
One participant stated: “I knew [i.e. learned] about my HIV status only after the death of my 
mother, because I hear[d] people saying that she died because of HIV.” Another participant 
said: “I was not told by my parents, but when I knew what the medication I was given every 
day was for, I realised that I was HIV-positive.” 
 
Figure 11 below describes the variation in the percentage of adherence, according to the mode 
of disclosure. Adherence to ART can be seen to be influenced by the mode of disclosure of 
HIV status, with the level of adherence seeming to be low when the adolescent discovers their 
HIV status indirectly by themselves. The lowest adherence levels were observed among 
adolescents who had become aware of their HIV-positive status after having undergone HIV 
voluntary counselling and testing (VCT). 
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Figure 11. Percentage of adherence mean in terms of mode of disclosure 
 
4.2.5. Feelings regarding the taking of ARVs 
 
Besides the responses received regarding the above-mentioned mode of disclosure, the 
majority of participants reported that they had accepted being informed of their HIV-positive 
status, and were, consequently, comfortable about taking ARV drugs. One participant stated: 
“I am feeling fine, because if I did not come to the clinic to take ARV, I could not [be] living 
as I am now.” Another participant said: “The reason why I was given this medication was 
because I was coughing too much. Now I am feeling better, and I like them.” 
 
Figure 12 below describes the proportion of participants who responded that they were feeling 
well (86.6%) and the proportion who stated that they did not feel well (13.3%).  
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Figure 12. Feelings regarding the taking of ARVs 
 
Figure 13 below describes the variation in the percentage of adherence according to the 
feelings expressed regarding the taking of ARVs. The adherence to ART seemed to be lower 
among the adolescents who were not comfortable regarding their HIV-positive status and 
about having to take ARV drugs. 
 
 
Figure 13. Percentage of adherence mean in terms of feelings regarding the taking of 
ARVs 
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4.2.6. Disclosure of HIV status to others (in terms of stigma) 
 
Fears of being discriminated against, as well as of losing their friends after disclosing their 
HIV-positive status to them, had resulted in 30% of the participants not having disclosed their 
HIV status to anyone. Two of their responses were: “I do not want to disclose my HIV status 
to anyone because of fearing to lose my friends” and “I am not comfortable at all to tell other 
people about my status.” A total of 46.66% of the participants stated that they were not willing 
to disclose their HIV status to other people than their close relatives. Some of them reported 
that they were comfortable enough to tell a limited number of close friends. The attitude of 
keeping their HIV-positive status as a strict secret even extended to the manner in which they 
kept their medications, with most of the adolescents (50%) keeping their tablets hidden in their 
bags. Many stated that they had to keep their medication in a very safe place, with some of 
them stating that they did so for security reasons, but others stating that they kept their ARVs 
in their bag in ‘secret’, in order to avoid letting other people know that they were taking 
ARVs. One of the participants stated: “I cannot take drug[s] when people are looking at me. I 
prefer to skip the dose if it is not possible to hide myself.”  
 
Figure 14 below describes the variation in the mean of adherence percentage according to fear 
of stigmatisation. Stigma consistently drove down the level of adherence to ART.  
 
Figure 14. Percentage of adherence mean in terms of willingness to disclose HIV status 
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4.2.7 Support system 
 
At least 33.3% of the participants stated that they attended the clinics alone, and another 40% 
stated that, if they were unable to attend the clinic, they had no one to assist them with 
collecting the ARVs at the clinic. They then had to miss out on the prescribed doses until they 
were themselves once more able to visit the clinic. The rest of the participants felt generally 
supported by their relatives, who accompanied them to the clinic, or who made themselves 
available to collect medicines for them when they were not able to attend the clinic. Most 
participants stated that they had been principally supported by an aunt or grandmother. 
Participants aged 17 and above had a tendency to attend the health facilities alone, because of 
not feeling comfortable enough to share their HIV-positive status with others. One participant 
commented: “If I am not able to come to the clinic for review or [a] refill, no one else can 
assist me.” 
 
Figure 15 below describes the variation in the percentage of adherence mean according to the 
nature of a ‘treatment buddy’. The adherence level to ART seemed to be lower among 
adolescents who were supported by their grandmothers than it was among those who attended 
the clinic with their parents. 
 
Figure 15. Percentage of adherence mean in terms of nature of treatment buddy 
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4.2.8. Medication side-effects 
 
The most frequently reported side-effects experienced by 43.33% of the participants were: 
skin rashes; headaches; nausea and/or vomiting; and dizziness. In general, most of the 
participants declared that they had tolerated their treatment, and that they had not experienced 
any side-effect during their treatment. The occurrence of side-effects was also mentioned as a 
problem, because concerned participants were supposed to attend the health facility 
immediately after stopping their medication, as was mentioned by one participant: “I once 
experience[d] skin rash while taking my medication. I stopped them, and waited for the money 
to go to the clinic for assistance.” The knowledge about side-effects and what to do when 
experiencing medicinal side-effects seemed to be limited and, in certain cases, it was even 
poor, especially where decision-making regarding attending the health facility for advice or 
assistance was concerned, with 23.3% of the participants responding that they were not aware 
of what to do when experiencing side-effects while taking ARVs. As one participant stated:  
I do not know what to do, because I was never been [sic] told at the clinic, that is why I was 
once told to stop my medication while waiting for the review date to go to explain to the 
doctor.  
 
Figure 16 below describes the variation in the percentage of adherence, according to the 
patients’ experience of side-effects. The adherence level to ART was found to be adversely 
lower among adolescents not experiencing side-effects than it was among those experiencing 
side-effects. 
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Figure 16. Percentage of adherence mean in terms of side-effect experience 
 
4.2.9. Knowledge regarding HIV/AIDS and the taking of ARVs 
 
Despite the finding that the participants in the study tended to be well-informed about 
HIV/AIDS and ARVs, 10% of them declared during the interview that they knew nothing 
about ARVs, whereas another 10% of the participants stated: “One day, I will be cured and 
stop [having] to take ARVs.” The above-mentioned facts constitute a challenge to adherance 
to medication, as was explained by 30% of the participants, who declared: “I am not aware of 
risks or [of] what can happen to me if I stop to take [i.e. taking] ARVs.” It was observed that 
the well-known modes of transmission of HIV were related to PMTCT. There seemed to be 
confusion about when to take the next dose of ARVs, when the time for taking it had already 
passed, with 20% of the participants declaring that they did not know what to do if they had 
forgotten to take their medication. They stated: “If I forget to take my treatment at the 
requested time, I will take it only [on] the following day, instead of taking the dose late.” 
 
Figure 17 below describes the variation in the percentage of adherence, according to the level 
of own knowledge. Adherence to ART seemed to be low among adolescents with sound 
knowledge of HIV and ARVs, and adversely high among adolescents with average knowledge 
of the above. 
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Figure 17. Percentage of adherence mean in terms of knowledge regarding HIV and 
ARVs  
 
4.2.10. Interaction between patient and health care providers 
 
Apart from the 10% of participants who declared that they were not comfortable with their 
health care providers, the majority stated that they were both satisfied with, and had 
confidence in, their respective health care providers. Most of the participants reported that 
they were satisfied with the manner in which they were treated at the facility, and that they felt 
confident with their health care provider, because “they [i.e. the health care providers] are not 
showing [up] their [i.e. the patients’] ignorance”, as one of the participants stated. The large 
majority of the participants who were residing near the health facilities in question were able 
to attend the facility monthly. However, in some cases, some participants (23.3%) had to 
travel more than 15 km to the clinic, and experienced difficulties with having to pay the 
transport costs.   
 
Figure 18 below describes the variation in adherence according to the distance required to be 
travelled between the health facility and the participant’s home. Adherence to ART seemed to 
decrease with the distance that the participants were based from the health facility concerned. 
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Figure 18. Percentage of adherence mean in terms of distance of the patient from the 
health facility 
 
4.2.11. Medication interaction with lifestyle and social habit 
 
In general, the participants indicated that they appreciated their medication for helping to 
maintain their wellness and survival. They generally stated that the taking of ARVs did not 
interfere with their adolescent lifestyle, and that it did not much impede their social habits. 
However, 3.33% of the participants declared that the “time to take my medication is not 
practical with [i.e. for] my daily lifestyle”. Some of the participants raised the problem of 
having to adhere strictly to the prescribed time of taking their medication, as prescribed by 
their health providers. One of the participants described the problem as follows: “I regularly 
missed one of my daily doses, because of the [i.e. its] correspondence of [i.e. with] my time to 
go to work.” Another participant stated: “I once missed my evening dose, because I came back 
late from school.”  
 
The problem of having to wait a long time at the health facility was cited by some participants 
(26.6%) as being a major challenge to adhering to the medical review or to the ARV refill 
schedule date. In connection with said issue, one participant stated: “I cannot attend school 
properly, because I am always spending ... all day at the clinic when I am coming for review.” 
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Another participant stated: “Sometimes I even give priority to school, especially when we are 
writing our exams.”  
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5. DISCUSSION 
 
5.1 Coverage of the current study 
 
The current study was conducted in order to identify the main factors (barriers) affecting 
HAART adherence among adolescents in selected Botswana clinics, so that recommendations 
could be proposed for improving adherence to ART.  
 
5.1.1. Barriers to adherence to the ART regimen 
 
The study examined several barriers to adherence described in the literature, by conducting a 
face-to-face interview with adolescent patients who had taken ARVs for more than one year. 
Some of the barriers discussed as affecting adolescent HAART adherence included stigma, the 
poorly conducted process of disclosure and social support, inadequate knowledge regarding 
both HIV and ARVs, the side-effects of having to take the medication, the distance of the 
patient from the health facility and the long waiting time endured at clinics, and the effect of 
having to take the medication on the patient’s social lifestyle. 
 
5.1.2. Percentage of adherence among adolescents studied 
 
The adherence rates found ranged between 44% and 94%, with the adherence percentage 
mean being 76.9%, which was less than the required 95% recommended in the literature to 
support the successful administration of ART. This percentage of adherence was also less than 
the reported 83% (Nwokike, 2004) that was found in the public health sector, but more than 
the reported 54% (Weiser, Wolfe, Bangsberg, Thior, Gilbert, Makhema, Kebaabetswe, 
Dickenson, Mompati, Essex & Marlink, 2003) that was found in the private sector, with both 
of these research studies having been conducted in Botswana. The reason for male adolescents 
(72.4%) being less adherent than were their counterpart female participants (80.4%) has yet to 
be revealed, unless the lack of adherence was related to the length of time that passed since 
starting treatment, which would imply that adolescents, especially female participants, are 
more likely to be adherent at the start of treatment. 
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The percentage of adherence was also found to be good with adolescents who were around the 
age of thirteen, and dropped progressively until they reached the age of nineteen, due probably 
to adolescent psychological growth, or to a decrease in adherence that was associated with the 
length of time over which ARVs were taken (i.e. pill fatigue). The above might also be the 
reason for the observed percentage of adherence being poor among participants attending 
senior secondary school.    
 
5.1.3. Inadequacies in the disclosure process 
 
The disclosure process appeared not to be being done in time and properly, with most 
participants discovering their HIV status themselves, either due to them being required to 
attend the health facility on an ARV scheduled day, or by them discovering why they had to 
take their prescribed medication. The mean age of discovery of own HIV-positive status was 
12 years. As was previously described in the relevant literature, health care workers and 
caregivers were reluctant to disclose to a child or an adolescent that they were HIV positive, 
due to the fear that their patients would have of their own stigmatisation and of the 
discrimination that would be likely to be perpetrated against them (Botswana, 2012, p. 71).  
 
According to the literature, one of the difficulties experienced during ART in children and 
adolescents have to cope with the disclosure process, which is supposed to be undertaken 
according to the sound judgement of support that is made available to the adolescent. The 
questions to be asked are when, where and how the disclosure should be done.  According to 
the Botswana ARV guidelines, providing children and adolescents with age-appropriate 
information about their illness is an essential part of HIV care, and, in coordination with the 
family and other clinic staff, is the responsibility of the treating practitioner (Botswana, 2012, 
p. 73). 
 
Disclosure of HIV status to adolescents should be considered as forming a process, rather than 
consisting of a one-time event. The levels of adherence were found to be good in the current 
study, with the disclosure process starting relatively early, when the patient was around the 
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age of ten, and then dropping progressively from when it took place from the age of eleven to 
a later age. The level of adherence was also found to be critical during the first two years after 
the disclosure, and the participants in the study were found to adhere to their treatment when 
the disclosure was undertaken by relatives or during PMTCT, compared with when 
adolescents discovered their HIV status by themselves, due to them being required to take 
ARVs, or after they had undergone voluntary HIV testing and counselling.  
 
The participants stated that they were not comfortable with disclosing their HIV status to 
another person than to a close relative. The large majority of them were reluctant to disclose 
their HIV status at school, with only a few participants being willing to disclose their HIV 
status to their close friends. The result of the study showed that adolescents who were not 
willing to disclose their HIV status to others also tended to have a lower level of adherence to 
ART than did their counterparts who were open about their HIV status.  
 
5.1.4. Obtaining social support from relatives 
 
People living with HIV in general and those who take ARVs in particular, require support 
from their relatives and circle of friends and acquaintances. In the process of preparing a 
patient for starting to take ARVs, an important element is the designation of a ‘treatment 
buddy’ to play a role in supporting the patient all along in their treatment. Adolescents are 
particularly in need of such a buddy, because of them being more likely to have a fragile 
mental state that is characterised by denial and the fear of infection, as well as by the impact 
that it will have on their future. They seem to require more support than do adults, because 
they still have a long way to go with their treatment, so that sharing their status with close 
friends or with a close teacher, for example, is likely to be important to, and supportive for, 
them. Supported adolescents might also avoid experiencing an attitude of low self-esteem.    
 
Social support from their relatives was found to be important in the current research study. 
Adolescents who attended the health facility accompanied by a direct relative, like their 
mother, aunt or a sibling, were found to adhere better to their treatment than did those who 
were accompanied by a grandmother, or did those coming alone to the facility. Unfortunately, 
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the majority of young infants and adolescents tended to live with one of their grandmothers in 
the rural areas, which constituted a permanent issue affecting adherence to ART in the rural 
area of the country. 
 
5.1.5. Tolerance of ARV regimen by patients 
 
The present study showed that the ARV regimen in Botswana was relatively well tolerated by 
the large majority of patients, thus the experiencing of side-effects was not considered as one 
of the major barriers to adherence. However, the adolescents not experiencing side-effects 
during their HIV treatment were, on the contrary, found to be less adherent to the treatment 
than were those in the other group. The above might be explained by the patients’ lack of 
knowledge about ARVs, with the adolescents not being interested in either knowing the side-
effects, nor what to do when they experienced them. At the same time, the health care 
providers, especially the pharmacists, seemed to neglect to use each visit that the patients paid 
the facility as an opportunity to explain and to inform them about what they could expect in 
terms of possible side-effects of the medication taken. Close attention seemed to be paid to the 
adherence counselling of patients only if a problem was detected.  
 
5.1.6. Lack of knowledge regarding adherence to the ART regimen  
 
The lack of knowledge regarding adherence to the ART regimen also seemed to affect the 
notion of what to do if one forgot to take ARVs at the prescribed time, which is essential 
information to provide when dispensing ARVs. The majority of the participants were found 
not to have experienced side-effects during their treatment. Knowledge regarding side-effects 
seemed not to have been sufficiently covered, with most of the participants still ignoring the 
possibility that they might experience side-effects, and not concerning themselves about 
ensuring that they knew what to do if they did experience them. 
 
5.1.7 Overall problems encountered in securing compliance with the ART regimen  
 
In general, the relationship between adolescents and health care workers did not seem to be 
problematic. However, the long-time (up to “all day”) that they were expected to wait for 
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treatment at the clinic, which impacted on their daily habits, especially school attendance, 
could have adversely affected their clinic and/or refill attendance. In addition, the participants 
in the study who stayed far from the health facility that they had to attend seemed to be less 
adherent to their treatment than were those who stayed close to the health facility, due to the 
unavailability of transport for the former patients. Said two problems that were revealed in the 
current study might constitute barriers for the adolescents needing to attend the clinic for a 
consultation or for a refill of their ARVs. Implementing a more efficient appointment 
scheduleling process and having a sufficient number of trained staff available to allow for the 
competent handling of patients might assist with balancing the progressively increasing 
workload and with shortening the waiting time experienced.   
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6. CONCLUSION AND RECOMMENDATIONS 
 
6.1 Objective of the current study 
 
Adolescents constitute a special segment of HIV-positive patients requiring particular 
attention from health care providers and from the entire National HIV/AIDS Programme, 
because of their particular psychological condition that inclines them not to adhere to the 
taking of ARVs. The main objective of the current research study was to find out why 
adolescents do not adhere to taking ARV drugs in selected clinics in Botswana. 
 
6.2 Deviation from the standard protocol regarding disclosure of HIV-positive status  
 
The entire process of when, where and how to disclose HIV status seemed not to follow that 
recommended in the literature. The majority of participants were found to learn about their 
HIV-positive status themselves through other ways than being told by caregivers or health 
care providers. Such a process could be seen to affect negatively the rate of adherence, and 
might also be the reason for the participants in the current study experiencing stigma that 
showed itself in them not being comfortable about disclosing their HIV status, and in the 
worsening of their poor adherence to their treatment.  
 
6.3 Barriers encountered to adherence to ART regimen 
 
Adolescents who were accompanied to the clinic by their grandmother and those attending the 
clinic alone tended to be less adherent to their treatment. Other factors, such as distance from 
the health facility and feelings regarding the taking of ARVs, were found to affect the rate of 
adherence negatively. However, contrary to common expectations, adolescents with a good 
level of knowledge and those not experiencing side-effects seemed to be less adherent to their 
prescribed treatment. Due to the distance to the health facilities, and the waiting time that the 
participants were required to spend there, some adolescents also expressed concerns regarding 
having to adhere to the schedule follow-up appointment, as doing so interfered with their 
social habits, like having to attend school and work.  
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6.4 Recommendations for health care workers 
 
Based on the above findings, it is recommended that health care workers should: 
– continuously evaluate the level of maturity of young HIV-positive patients and discuss, 
at the appropriate moment, where and how to disclose their status to them; 
– continuously insist on the importance of disclosing the HIV-positive status of patients 
to them, with the main objective of assisting adolescents in choosing should be their 
treatment buddy; 
– encourage HIV-positive adolescents during each of their clinic visits to take their 
ARVs, and reinforce their knowledge about HIV and ARVs; 
– discuss with the adolescent’s parents the importance and the choice of a treatment 
buddy; and 
– assist caretakers to teach young children the names of their medicines and how they 
should be taken. They should also set aside sufficient time during a follow-up visit to 
review the adolescent patient’s knowledge regarding HIV and ARVs and to teach them 
that their medicines are assisting to restore health by increasing the number of CD4 
cells. The caretakers should also actively insist on the fact that young patients can live 
healthy lives and that they are as equally capable of thinking about, and planning, their 
lives as are HIV-negative adolescents. 
 
6.5 Recommendations for the ARV rollout programme 
 
Recommendations for the ARV rollout programme include: 
– extending the ARV dispensing service at health posts that are close to the community, 
in order to address the barrier of both distance and congestion at the clinic; and  
– attaching special consideration to the peer support of adolescents in the rural areas, in 
line with the support that is recommended for, and organised in, towns. Rural health 
facilities must also be supported to implement HIV-positive peer support networks, 
such as adolescent clubs, where the HIV-positive adolescents can meet and support 
one another. Discussion within peer supports networks must be extended to questions 
related to sexual and reproductive health. 
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ADDENDA 
Addendum A Tables of results 
 
I. Demographic data 
 
Table 2 
Population distribution by age and sex 
 
Age in Years Males Females Total 
18 years 1 0 1 
16 years 0 1 1 
16 years 1 0 1 
14 years 0 1 1 
15 years 0 1 1 
15 years 1 0 1 
13 years 0 1 1 
13 years 1 0 1 
13 years 0 1 1 
16 years 1 0 1 
17 years 0 1 1 
13 years 0 1 1 
14 years 1 0 1 
14 years 1 0 1 
15 years 1 0 1 
13 years 0 1 1 
14 years 0 1 1 
16 years 0 1 1 
14 years 0 1 1 
15 years 0 1 1 
15 years 1 0 1 
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16 years 0 1 1 
20 years 0 1 1 
20 years 0 1 1 
13 years 1 0 1 
20 years 0 1 1 
17 years 0 1 1 
20 years 1 0 1 
19 years 1 0 1 
18 years 1 0 1 
Total 13 17 30 
 
Table 3 
Distribution of population level of education by sex 
 
Education level Male Female Total 
Primary 4 4 8 
Secondary Junior 6 10 16 
Secondary Senior 3 1 4 
Tertiary 0 0 0 
Never Been to School 0 2 2 
Total 13 17 30 
 
II. Stigma and Disclosure of HIV status 
 
Table 4 
Length of been aware of HIV status by sex 
 
Duration in years Male Female Total 
1-2 years 3 8 11 
3-4 Years 4 2 6 
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>5 years 6 7 13 
Total 13 17 30 
 
 
Table 5 
Age of disclosure by sex 
 
Age in Years Males Females Age of Disclosure 
18 years 1 0 15 
16 years 0 1 10 
16 years 1 0 12 
14 years 0 1 12 
15 years 0 1 13 
15 years 1 0 10 
13 years 0 1 13 
13 years 1 0 9 
13 years 0 1 7 
16 years 1 0 15 
17 years 0 1 6 
13 years 0 1 9 
14 years 1 0 7 
14 years 1 0 13 
15 years 1 0 18 
13 years 0 1 11 
14 years 0 1 10 
16 years 0 1 13 
14 years 0 1 12 
15 years 0 1 13 
15 years 1 0 6 
16 years 0 1 19 
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20 years 0 1 20 
20 years 0 1 9 
13 years 1 0 18 
20 years 0 1 15 
17 years 0 1 16 
20 years 1 0 14 
19 years 1 0 12 
18 years 1 0 12 
Total 13 17  
 
Table 6 
Mode of disclosure 
 
 Male Female Total 
I was not feeling well then I went for HIV test 10 4 14 
I was always brought to the clinic during ARV clinic schedule 1 3 4 
Since the death of my mother 0 1 1 
When I discover that I was taking ARVs 1 3 4 
I was told by relatives 1 3 4 
I was told at the clinic 0 0 0 
Voluntary Counselling and Testing 0 2 2 
During PMTCT 0 1 1 
Total 13 17 30 
 
Table 7 
Feeling toward taking ARV 
 
 Male Female Total 
Well 10 16 26 
Not Well 3 1 4 
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Total 13 17 30 
 
Table 8 
Disclosure of HIV status to others 
 
 Males Females Total 
Who have you told about your status    
Parents 3 3 6 
Aunty 0 3 3 
Siblings 2 6 8 
Garand Mother 0 0 0 
Close Friends 1 1 2 
School teacher 0 2 2 
No one 7 2 9 
Total 13 17 30 
Who else are you willing to disclose to    
Siblings 2 2 4 
Aunty/Uncle 2 1 3 
Friends 0 8 8 
Teacher 1 0 1 
No one 8 6 14 
Total 13 17 30 
Are you comfortable to disclose your status to a friend    
Yes 4 14 18 
No 9 3 12 
 13 17 30 
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III. Support system 
 
Table 9 
Support system 
 
 Male Female Total 
Who is accompanying you to the Clinic    
Parents 2 4 6 
Grand Mother 2 3 5 
Aunty 1 6 7 
Siblings 1 1 2 
Teacher 0 0 0 
No one 7 3 10 
Total 13 17 30 
If not around, who else    
Parents 0 2 2 
Grand Mother 2 4 6 
Aunty 2 4 6 
Siblings 2 0 2 
Neighbour 1 1 2 
Friend 0 0 0 
No one 6 6 12 
Total 13 17 30 
 
IV. Medication side-effects 
 
Table 10 
Side-effects 
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 Male Female Total 
Experienced Side-Effects    
Skin Rash 2 1 3 
Headache 1 1 2 
Nausea/Vomiting 1 1 2 
Swollen Body 0 1 1 
Coughing/Dyspnoea 0 1 1 
Dizziness 3 1 4 
No side-effects 6 11 17 
Total 13 17 30 
    
Expecting side-effects    
Skin Rash 4 5 9 
Headache 0 0 0 
Nausea/Vomiting 1 1 2 
Dizziness 2 3 5 
Insomnia 0 0 0 
Dyspnoea 0 0 0 
Do not know 6 8 14 
Total 13 17 30 
    
What to do if side-effect    
Stop the treatment  0 0 0 
Stop treatment and go to the clinic 3 0 3 
Continue treatment and go to the clinic 4 6 10 
To go to the clinic 4 6 10 
Do not know 2 5 7 
Total 13 17 30 
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V. Adequate information or knowledge 
 
Table 11 
Knowledge about HIV/AIDS and ARVs 
 
 Male Female Total 
What are risks of HIV    
Unprotected sex 6 3 9 
Sharing a razor 1 2 3 
Blood contact 3 5 8 
Through breast milk 2 5 7 
During delivary 1 2 3 
Total 13 17 30 
    
What do you know about HIV medications    
They are taken every days 1 2 3 
They are not curing HIV 1 4 5 
They are taken lifelong 3 0 3 
They are reducing the rate of HIV 1 4 5 
They are taken by someone who have HIV 0 1 1 
They are improving the rate of CD4 2 2 4 
They are prolonging life 2 3 5 
They are not taken with alcohol, drugs or traditional medicines 1 0 1 
I do not know 2 1 3 
Total 13 17 30 
    
What are the risks of stopping ARVs     
One can lose life if stopping ARVs 3 3 6 
ARVs are not curing HIV 3 9 12 
One day I will be cured and stop ARVs 1 2 3 
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I do not know 6 3 9 
Total 13 17 30 
    
What to do if you forget to take your medication    
I have to tell relatives so that they can remind me 0 2 2 
I will take the following day 1 1 2 
I will go to the Clinic the following day 3 4 7 
I will take the dose as soon when I remember 7 6 13 
I do not know 2 4 6 
Total 13 17 30 
 
 
VI. Interaction with Health Service 
 
Table 12 
Interaction between patient and health care provider 
 
 Male Female Total 
Do you feel you can ask any questions from your health provider    
Yes 11 16 27 
No 2 1 3 
Total 13 17 30 
    
Do you feel confident with him    
Yes 12 17 29 
No 1 0 1 
Total 13 17 30 
    
Are you satisfied with the manner which the health staff assist 
you 
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Yes 13 17 30 
No 0 0 0 
Total 13 17 30 
 
VII. Medication interaction with lifestyle and social habit 
 
Table 13 
ARV interaction with lifestyle and daily habit 
 
 Male Female Total 
Where do you keep your medication    
On top of the table 1 5 6 
On top of the wardrobe 1 2 3 
In the drawer 3 2 5 
In the bag 8 7 15 
In a very safe place 0 1 1 
Total 13 17 30 
    
Is the time of taking your medication practical    
Yes 13 16 29 
No 0 1 1 
Total 13 17 30 
    
Interaction on other aspects of the lifestyle     
Interfering with the time to go to church 0 1 1 
Interfering with the time to go to school  3 3 6 
Interfering with the time to go to work 2 1 3 
No interaction at all 8 12 20 
Total 13 17 30 
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VIII. Other interactions 
 
Table 14 
Other interactions 
 
 Male Female Total 
How far are you staying from the Clinic    
< 5 km 9 9 18 
5-10 km 1 2 3 
10-15 km 1 1 2 
>15 km 2 5 7 
Total 13 17 30 
    
Are you able to come to the Clinic every Month    
Yes 9 15 24 
No 4 2 6 
Total 13 17 30 
    
Is there anyone else who can collect ARVs for you if not able to 
come to the clinic 
   
Yes 13 17 30 
No 0 0 0 
Total 13 17 30 
    
How is your HIV status affect your social habit    
I cannot attend school properly because I am always spending 
the all day at the clinic when I am coming for review 
5 3 8 
No change at all 8 14 22 
Total 13 17 30 
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Table 15 
Percentage of adherence and factors affecting adherence 
 
Age 
(years)  
Male Female Adherence 
(%) 
Length of 
disclosure 
(years) 
Mode of 
disclosure 
Distance 
(Km) 
18  1 0 90 3 A <5 
16  0 1 87 6 B 5-10 
16  1 0 69 4 C <5 
14  0 1 91 2 C 5-10 
15  0 1 89 2 A <5 
15  1 0 67 5 C <5 
13  0 1 90 1 D <5 
13  1 0 94 4 C <5 
13  0 1 89 6 C <5 
16  1 0 78 1 C <5 
17  0 1 90 9 C <5 
13  0 1 68 4 E >15 
14  1 0 71 7 C <5 
14  1 0 57 1 C <5 
15  1 0 71 7 E <5 
13  0 1 80 2 A >15 
14  0 1 86 4 E <5 
16  0 1 71 3 E <5 
14  0 1 44 2 E 5-10 
15  0 1 91 2 C <5 
15  1 0 75 9 C >15 
16  0 1 92 7 D >15 
20  0 1 63 1 F >15 
20  0 1 87 11 G <5 
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13  1 0 83 5 D >15 
20  0 1 91 5 C <5 
17  0 1 59 1 A >15 
20  1 0 67 6 E >15 
19  1 0 58 7 F 10-15 
18  1 0 61 6 E 10-15 
Total 13 17 Χ 76.96 X 4.3    
 
A: by coming to the clinic during ARV clinic 
B: since the death of my mother 
C: I was always sick then went for HIV test 
D: I was told by relatives 
E: By taking ARVs 
F: VCT 
G: PMTCT 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
60 
 
Addendum B  Study questionnaire 
 
INTERVIEW SCHEDULE 
a) Attitude towards their HIV status and medication 
 
(i) How long have you been aware about you HIV status? 
(ii) How did you find it out? 
(iii) What is your feeling towards taking ARV? 
 
b) Disclosure 
 
(i) Who have you told about your status? For example: family member, friend, at 
school. 
(ii) Who else are you willing to disclose to? 
(iii) Are you comfortable to disclose to a friend that you are taking HIV medication?  
 
c) Support system 
 
(i) Who is accompanying you to the clinic for medical review? 
(ii) If that person is not available, who else can be there for you? 
 
d) Side-effects 
 
(i) What side-effect have you experienced while on ARV? 
(ii) Do you know what side-effect to expect from ARV? 
(iii) Do you know what to do if you experience side-effect? 
 
e)  Adequate information or knowledge 
 
(i) What are risks of HIV infection?     
(ii) What do you know about HIV medication? 
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(iii)What are risks of stopping HIV medication? 
(iv) Do you know what to do if you forget to take your medication? 
 
f) Interaction between patient and client provider 
 
(i) Do you feel you can ask any questions from your health provider? 
(ii) Do you feel confident with him? 
(iii) Are you satisfied with the manner in which the health staffs assist you? 
 
 
g) Interaction of medication to lifestyle and daily habits 
 
(i) Where do you keep your medication in the house? At boarding school? 
(ii) What time of the day do you take your medication? Is it practical for you? 
(iii) Is there any other aspect of your lifestyle that is interacting with your time of 
taking your medication? 
 
h) Any other 
 
(i) How far do you live from the clinic? 
(ii) Can you get to the clinic easily and are you able to come every month? 
(iii) If you are sick and not able to come to the clinic, is there anyone who can fetch the 
medication for you? 
(iv) How is your HIV status or your medication affecting your social habits? 
 
i) Demographic factors 
 
(i) What is your age? 
(ii) What is you gender? 
(iii) What is you education level? 
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Addendum C Consent for research 
 
 
 
 
STELLENBOSCH UNIVERSITY 
 
 
 
PARTICIPANT INFORMATION LEAFLET AND ASSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
Factors that affect adherence to antiretroviral therapy among HIV/AIDS Adolescent patients at 
selected Palapye Clinics 
What is RESEARCH? 
Research is something we do to find new knowledge about the way things (and people) work.  
We use research projects or studies to help us find out more about disease or illness. Research 
also helps us to find better ways of helping, or treating children who are sick. 
 
What is this research project all about? 
The research is projecting to identify main reasons influencing adolescents to not taking 
correctly their ARV drugs in order to assist health care workers to improve adherence 
counselling before and during the ARV treatment 
Why have I been invited to take part in this research project? 
You have been invited to take part to this research project because your age is corresponding 
to the age group defined by the study and you are collecting ARV drugs in this clinic today   
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Who is doing the research? 
I am Doctor Kambale, I am based at Maokatumo clinic but I am also consulting patients at 
Maunatlala and Lerala clinic, this research project is part of my study, I am doing distance 
learning from Stellenbosch University in South Africa, and I will be assisted by Mrs Neo 
Mothusi who is the counsellor in the clinic.  
 
What will happen to me in this study? 
I will be assisted by the counsellor, and together we will invite you to seat in this office and we 
will ask you some questions about how you are taking your ARV drugs, we expect you to be as 
open as possible and feel free to respond to our questions, and at any time you can tell us to 
stop the conversation. We will also need to count your remaining pills and compare the 
number to the number of pills given to you during the last visit to the clinic, that will assist us 
to have an idea of how many pills did you take during this period. You have to know that your 
identity will not be recorded anywhere, we only need to know your opinion about your 
treatment. After the conversation I will keep all the information I my secured laptop where no 
one else will accede to the information, the conversation may take 30 to 40 minutes  
 
Can anything bad happen to me? 
You know, every things or conversation related to HIV may be misunderstood and mentally 
frustrate you, that why we are together with your counsellor who learned to understand you 
since more than a year now before and during your treatment. But it is only a conversation; 
we will not use anything which can harm you physically or mentally. We will ensure your 
safety and comfort through the process. 
 
Can anything good happen to me? 
Yes, the study may assist us health care workers to understand patients in your age group in 
order to improve our ability to continue supporting you all along your treatment, which is an 
important part of your treatment because support is all you need to maintain a good 
adherence to your medication.  
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Will anyone know I am in the study? 
No, any one will know, as I told you I will keep everything in my secured laptop, and will 
report all information to the University but without mentioning, neither your identity nor the 
clinic where the information is coming from.  
 
Who can I talk to about the study? 
 
 You can contact your local counsellor any time; if he/she cannot 
assist you he/she will contact me. 
 
 
 
 
 
What if I do not want to do this? 
It is your right to refuse to take part to the study even if your parents have agreed, but that will 
not affect your future treatment or the relationship with us. 
 
Identification of investigators 
If you have any questions or concerns about the research, please feel free to contact 
 
Dr. HerveNzerekaKambale (Principal Investigator) 
Maokatumo Clinic, P.O. Box 153, Maokatumo 
Tel (work): 4958433 
Cell: 75420524 
 
Dr. Greg Munro (Study Leader) 
P.O. Box:  
E-mail address: greg@sybaweb.co.za 
Tel: 0027 836292567 
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Mrs Neo Mothusi (aid counsellor) 
Maokatumo Clinic, P.O. Box 153, Maokatumo 
Tel (work): 4958433 
Cell: 71662900 
 
Ms Nelly Moupo (aid counsellor) 
Maunatlala Clinic, P.O.Box 71 Palapye 
Tel (work): 4958235 
Cell: 71408553 
 
Mr WaboTathayaone (aid counsellor) 
Lerala Clinic, P.O. Box 54 Lerala 
Tel (work): 4954019 
Cell: 75478611 
 
Do you understand this research study and are you willing to take part in it?   
YES  NO 
Has the researcher answered all your questions? 
YES  NO 
 
Do you understand that you can pull out of the study at any time? 
YES  NO 
_________________________  ____________________  
Signature of Child   Date 
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STELLENBOSCH UNIVERSITY 
CONSENT TO PARTICIPATE IN RESEARCH 
 
 
Factors that affect adherence to antiretroviral therapy among HIV/AIDS Adolescent patients at 
selected Palapye Clinics 
You are asked to participate in a research study conducted by Dr. HerveNzerekaKambale, 
from the Africa Centre for HIV/AIDS Management at Stellenbosch University. The result of 
this research study will be contributed to thesis.  You were selected as a possible participant in 
this study because you are aged between 18-20 years and you are taking antiretroviral drugs 
since more than a year. 
 
1. PURPOSE OF THE STUDY 
The purpose of this research study is to identify reasons influencing poor adherence to 
antiretroviral treatment among adolescent patients  
 
2. PROCEDURES 
If you volunteer to participate in this study, we would ask you to do the following things: 
Location 
To be interviewed in a private room respecting your confidentiality 
Consent procedures 
After introducing ourselves and explaining to you all the procedure, You will be given an 
information sheet explaining and describing briefly the study and its objectives, you will be 
allowed to ask questions or request more clarifications before to give us a verbal and written 
consent 
Stellenbosch University  http://scholar.sun.ac.za
 
 
67 
 
Interview 
After giving your consent, a face-to-face interview will be conducted by me, assisted by the 
local counsellor who will help me by explaining everything in Setswana if you have difficult 
to talk in English.  
Duration  
 
The length of the interview will be approximately 40 minutes 
 
3. POTENTIAL RISKS AND DISCOMFORTS 
 
As any conversation related to HIV/AIDS, you cannot feel comfortable to answer some 
personal questions during the interview, that is also the reason why the interview is conducted 
with the local counsellor who has been with you in this facility for long time. And you can 
also feel free to not respond or stop the interview at any time, and you have to know that it 
will not affect your future treatment. 
 
As I say previously, HIV field is very sensitive; if you feel that we ask you something which is 
personal which may frustrate you, you are free to ask us to terminate this study.   
 
4. POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
 
Description of reasons contributing to poor adherence to antiretroviral treatment among 
adolescent should contribute to the improvement of adherence counselling before and during 
the treatment which is one of the factor contributing to the success of antiretroviral therapy. 
 
The success of the antiretroviral therapy will improve the quality of life of adolescents and 
will reduce the transmission of the disease among the most productive and active age group of 
the society. 
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5. PAYMENT FOR PARTICIPATION 
Participants to this study will not receive any form of payment  
 
6. CONFIDENTIALITY 
 
Any information that is obtained in connection with this study and that can be identified with 
you will remain confidential and will be disclosed only with your permission or as required by 
law. Confidentiality will be maintained by means of information obtain from you will be kept 
in a locked computer, your name will not be mentioned anywhere nor the clinic where the 
information was obtained. No other person will have access to the computer password, and all 
information will be deleted three months after the end of the study. There will be no way of 
identifying that you have participated in this study. 
 
At the end of the study, encoded result will be submitted to the Africa Centre for HIV/AIDS 
Management and Ministry of Health of Botswana. 
 
7. PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, you 
may withdraw at any time without consequences of any kind.  You may also refuse to answer 
any questions you don’t want to answer and still remain in the study. The investigator may 
withdraw you from this research if circumstances arise which warrant doing so.  
 
At any time during the interview, if we observe that you are becoming frustrated we can 
decide together with the counsellor to terminate this interview. 
 
8. IDENTIFICATION OF INVESTIGATORS 
If you have any questions or concerns about the research, please feel free to contact 
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Dr. HerveNzerekaKambale (Principal Investigator) 
Maokatumo Clinic, P.O. Box 153, Maokatumo 
Tel (work): 4958433 
Cell: 75420524 
 
Dr. Greg Munro (Study Leader) 
Tel: 0027 836292567 
 
Mrs Neo Mothusi (Co-Investigator) 
Maokatumo Clinic, P.O. Box 153, Maokatumo 
Tel (work): 4958433 
Cell: 71662900 
 
Ms Nelly Moupo (Co-Investigator) 
Maunatlala Clinic, P.O.Box 71 Palapye 
Tel (work): 4958235 
Cell: 71408553 
 
Mr WaboTathayaone (Co-Investigator) 
Lerala Clinic, P.O. Box 54 Lerala 
Tel (work): 4954019 
Cell: 75478611 
 
9.   RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent at any time and discontinue participation without penalty.  
You are not waiving any legal claims, rights or remedies because of your participation in this 
research study.  If you have questions regarding your rights as a research subject, contact Ms 
MaléneFouché [mfouche@sun.ac.za; 021 808 4622] at the Division for Research 
Development. 
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SIGNATURE OF RESEARCH SUBJECT OR LEGAL REPRESENTATIVE 
 
The information above was described to [me/the subject/the participant] by [name of relevant 
person] in [Setswana/English/other] and [I am/the subject is/the participant is] in command of 
this language or it was satisfactorily translated to [me/him/her].  [I/the participant/the subject] 
were given the opportunity to ask questions and these questions were answered to [my/his/her] 
satisfaction.  
[I hereby consent voluntarily to participate in this study/I hereby consent that the 
subject/participant may participate in this study.] I have been given a copy of this form. 
 
________________________________________ 
Name of Subject/Participant 
 
________________________________________ 
Name of Legal Representative (if applicable) 
 
________________________________________   ______________ 
Signature of Subject/Participant or Legal Representative  Date 
 
 
SIGNATURE OF INVESTIGATOR  
 
I declare that I explained the information given in this document to __________________ 
[name of the subject/participant] and/or [his/her] representative ____________________ 
[name of the representative]. [He/she] was encouraged and given ample time to ask me any 
questions. This conversation was conducted in [Setswana/*English/*other] and [no translator 
was used/this conversation was translated into ___________ by 
_______________________]. 
 
________________________________________  ______________ 
Signature of Investigator     Date 
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STELLENBOSCH UNIVERSITY 
PARENTS/GUARDIANS CONSENT TO PARTICIPATE IN RESEARCH 
 
 
Factors that affect adherence to antiretroviral therapy among HIV/AIDS Adolescent patients at 
selected Palapye Clinics 
You are asked to authorize your child to participate in a research study conducted by Dr. 
HerveNzerekaKambale, from the Africa Centre for HIV/AIDS Management at Stellenbosch 
University. The result of this research study will be contributed to thesis.  Your child was 
selected as a possible participant in this study because he is aged between 13-17 years and he 
is taking antiretroviral drugs since more than a year. 
 
1. PURPOSE OF THE STUDY 
The purpose of this research study is to identify reasons influencing poor adherence to 
antiretroviral treatment among adolescent patients  
 
2. PROCEDURES 
If you volunteer to participate in this study, we would ask your child to do the following 
things: 
Location 
To be interviewed in a private room respecting his/her confidentiality 
Consent procedures 
After introducing ourselves and explaining to you all the procedure, You will be given an 
information sheet explaining and describing briefly the study and its objectives, you will be 
Stellenbosch University  http://scholar.sun.ac.za
 
 
72 
 
allowed to ask questions or request more clarifications before to give us a verbal and written 
consent to interview your child. 
Interview 
After giving your consent, a face-to-face interview will be conducted by me, assisted by the 
local counsellor who will help me by explaining everything in Setswana if you have difficult 
to talk in English and to support your child psychologically if he/she is not feeling comfortable 
with our questions. We will also need to count his/her remaining pills and compare the number 
to the number of pills given during the last visit to the clinic, that will assist us to have an idea 
of how many pills did he/she takes during this period. 
Duration  
The length of the interview will be approximately 40 minutes 
 
3. POTENTIAL RISKS AND DISCOMFORTS 
As any conversation related to HIV/AIDS, your child can not feel comfortable to answer some 
personal questions during the interview, that is also the reason why the interview is conducted 
with the local counsellor who has been with you in this facility for long time. And your child 
can also feel free to not respond or stop the interview at any time, and you have to know that it 
will not affect his/her future treatment. 
As I say previously, HIV field is very sensitive; if you feel that we ask your child something 
which is personal which may frustrate him/her, you are free to ask us to terminate this study.   
 
4. POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
Description of reasons contributing to poor adherence to antiretroviral treatment among 
adolescent should contribute to the improvement of adherence counselling before and during 
the treatment which is one of the factor contributing to the success of antiretroviral therapy. 
The success of the antiretroviral therapy will improve the quality of life of adolescents and 
will reduce the transmission of the disease among the most productive and active age group of 
the society. 
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5. PAYMENT FOR PARTICIPATION 
Participants to this study will not receive any form of payment  
 
6. CONFIDENTIALITY 
Any information that is obtained in connection with this study and that can be identified with 
your child will remain confidential and will be disclosed only with your permission or as 
required by law. Confidentiality will be maintained by means of information obtain from 
him/her will be kept in a locked computer, his/her name will not be mentioned anywhere nor 
the clinic where the information was obtained. No other person will have access to the 
computer password, and all information will be deleted three months after the end of the 
study. There will be no way of identifying that you have participated in this study. 
At the end of the study, reports not containing any of participant particulars will be submitted 
to the Africa Centre for HIV/AIDS Management and Ministry of Health of Botswana. 
 
7. PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, you 
may withdraw at any time without consequences of any kind.  You may also tell to your child 
to not answer any questions you don’t want him/her to answer and still remain in the study. 
The investigator may withdraw you from this research if circumstances arise which warrant 
doing so.  
 
At any time during the interview, if we observe that your child is becoming frustrated we can 
decide together with the counsellor to terminate this interview. 
 
8. IDENTIFICATION OF INVESTIGATORS 
If you have any questions or concerns about the research, please feel free to contact 
 
Dr. HerveNzerekaKambale (Principal Investigator) 
Maokatumo Clinic, P.O. Box 153, Maokatumo 
Tel (work): 4958433 
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Cell: 75420524 
 
Dr. Greg Munro (Study Leader) 
P.O. Box:  
E-mail address: greg@sybaweb.co.za 
Tel: 0027 836292567 
 
Mrs Neo Mothusi (aid counsellor) 
Maokatumo Clinic, P.O. Box 153, Maokatumo 
Tel (work): 4958433 
Cell: 71662900 
 
Ms Nelly Moupo (aid counsellor) 
Maunatlala Clinic, P.O.Box 71 Palapye 
Tel (work): 4958235 
Cell: 71408553 
 
Mr WaboTathayaone (aid counsellor) 
Lerala Clinic, P.O. Box 54 Lerala 
Tel (work): 4954019 
Cell: 75478611 
 
9.   RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent at any time and discontinue your child participation without 
penalty.  You are not waiving any legal claims, rights or remedies because of your 
participation in this research study.  If you have questions regarding your rights as a research 
subject, contact Ms MaléneFouché [mfouche@sun.ac.za; 021 808 4622] at the Division for 
Research Development. 
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SIGNATURE OF RESEARCH SUBJECT OR LEGAL REPRESENTATIVE 
 
The information above was described to [me/the parent/guardian] by [name of relevant 
person] in [Setswana/English/other] and [I am/the parent is/the guardian is] in command of 
this language or it was satisfactorily translated to [me/him/her].  [I/the parent/the guardian] 
were given the opportunity to ask questions and these questions were answered to [my/his/her] 
satisfaction.  
[I hereby consent voluntarily to participate in this study/I hereby consent that the 
subject/participant may participate in this study.] I have been given a copy of this form. 
 
________________________________________ 
Name of Subject/Participant 
 
________________________________________ 
Name of Legal Representative  
 
________________________________________   ______________ 
Signature Legal Representative                                         Date 
 
SIGNATURE OF INVESTIGATOR  
 
I declare that I explained the information given in this document to __________________ 
[name of the subject/participant] and/or [his/her] representative ____________________ 
[name of the representative]. [He/she] was encouraged and given ample time to ask me any 
questions. This conversation was conducted in [Setswana/*English/*other] and [no translator 
was used/this conversation was translated into ___________ by 
_______________________]. 
 
________________________________________  ______________ 
Signature of Investigator     Date 
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